Report cover image

Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 205 Pages
SKU # APRC20279389

Description

Summary

According to APO Research, the global TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the TNF Inhibitors for the Treatment of Plaque Psoriasis market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the TNF Inhibitors for the Treatment of Plaque Psoriasis market include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for TNF Inhibitors for the Treatment of Plaque Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for TNF Inhibitors for the Treatment of Plaque Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for TNF Inhibitors for the Treatment of Plaque Psoriasis sales, projected growth trends, production technology, application and end-user industry.

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company

Chia Tai Tianqing Pharmaceutical
Innovent Biologics
Sino Cell Technologies
Samsung Bioepis
Hangzhou Bozhirui Biopharmaceuticals
Hisun Pharmaceuticals
Bio-Thera Solutions
YL Biologics
UCB
Teva
Sandoz
Pfizer
Janssen Biotech
Coherus BioSciences
Celltrion
Boehringer Ingelheim Pharmaceuticals
Biocon Biologics
Amgen
AbbVie
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

Adalimumab
Certolizumab pegol
Etanercept
Infliximab
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

Hospital and Clinic
Retail Pharmacies
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global TNF Inhibitors for the Treatment of Plaque Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions TNF Inhibitors for the Treatment of Plaque Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify TNF Inhibitors for the Treatment of Plaque Psoriasis significant trends, drivers, influence factors in global and regions.
6. To analyze TNF Inhibitors for the Treatment of Plaque Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the TNF Inhibitors for the Treatment of Plaque Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global TNF Inhibitors for the Treatment of Plaque Psoriasis industry.
Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of TNF Inhibitors for the Treatment of Plaque Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

205 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
1.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume (2020-2031)
1.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 TNF Inhibitors for the Treatment of Plaque Psoriasis Market Dynamics
2.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
3 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Company
3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Revenue Ranking in 2024
3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (2020-2025)
3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Company (2020-2025)
3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price by Company (2020-2025)
3.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Ranking (2023-2025)
3.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Manufacturing Base and Headquarters
3.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Product Type and Application
3.8 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 TNF Inhibitors for the Treatment of Plaque Psoriasis Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
4.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Type Introduction
4.1.1 Adalimumab
4.1.2 Certolizumab pegol
4.1.3 Etanercept
4.1.4 Infliximab
4.1.5 Other
4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type
4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2020-2031)
4.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Type (2020-2031)
4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type
4.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2020-2031)
4.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type (2020-2031)
5 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
5.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Retail Pharmacies
5.1.3 Other
5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application
5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2020-2031)
5.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Application (2020-2031)
5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application
5.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2020-2031)
5.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application (2020-2031)
6 TNF Inhibitors for the Treatment of Plaque Psoriasis Regional Sales and Value Analysis
6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2020 VS 2024 VS 2031
6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2020-2031)
6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2020-2025
6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2026-2031)
6.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2020-2031)
6.4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region: 2020-2025
6.4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2026-2031)
6.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
6.6.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
6.7.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
6.8.2 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
6.9.2 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2020-2031)
6.10.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2024 VS 2031
7 TNF Inhibitors for the Treatment of Plaque Psoriasis Country-level Sales and Value Analysis
7.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country: 2020 VS 2024 VS 2031
7.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2031)
7.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2025)
7.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2026-2031)
7.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2020-2031)
7.4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2020-2025)
7.4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.5.2 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.5.3 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.6.2 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.6.2 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.8.2 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.9.2 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.9.3 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.10.2 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.11.2 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.12.2 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.13.2 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.16.2 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.16.3 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.17.2 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.18.2 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.19.2 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.19.3 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.20.2 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.22.2 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.23.2 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.24.2 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.25.2 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.26.2 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.28.2 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.29.2 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.30.2 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.31.2 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2020-2031)
7.32.2 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Chia Tai Tianqing Pharmaceutical
8.1.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8.2 Innovent Biologics
8.2.1 Innovent Biologics Comapny Information
8.2.2 Innovent Biologics Business Overview
8.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.2.5 Innovent Biologics Recent Developments
8.3 Sino Cell Technologies
8.3.1 Sino Cell Technologies Comapny Information
8.3.2 Sino Cell Technologies Business Overview
8.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.3.5 Sino Cell Technologies Recent Developments
8.4 Samsung Bioepis
8.4.1 Samsung Bioepis Comapny Information
8.4.2 Samsung Bioepis Business Overview
8.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.4.5 Samsung Bioepis Recent Developments
8.5 Hangzhou Bozhirui Biopharmaceuticals
8.5.1 Hangzhou Bozhirui Biopharmaceuticals Comapny Information
8.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
8.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
8.6 Hisun Pharmaceuticals
8.6.1 Hisun Pharmaceuticals Comapny Information
8.6.2 Hisun Pharmaceuticals Business Overview
8.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.6.5 Hisun Pharmaceuticals Recent Developments
8.7 Bio-Thera Solutions
8.7.1 Bio-Thera Solutions Comapny Information
8.7.2 Bio-Thera Solutions Business Overview
8.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.7.5 Bio-Thera Solutions Recent Developments
8.8 YL Biologics
8.8.1 YL Biologics Comapny Information
8.8.2 YL Biologics Business Overview
8.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.8.5 YL Biologics Recent Developments
8.9 UCB
8.9.1 UCB Comapny Information
8.9.2 UCB Business Overview
8.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.9.5 UCB Recent Developments
8.10 Teva
8.10.1 Teva Comapny Information
8.10.2 Teva Business Overview
8.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.10.5 Teva Recent Developments
8.11 Sandoz
8.11.1 Sandoz Comapny Information
8.11.2 Sandoz Business Overview
8.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.11.5 Sandoz Recent Developments
8.12 Pfizer
8.12.1 Pfizer Comapny Information
8.12.2 Pfizer Business Overview
8.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.12.5 Pfizer Recent Developments
8.13 Janssen Biotech
8.13.1 Janssen Biotech Comapny Information
8.13.2 Janssen Biotech Business Overview
8.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.13.5 Janssen Biotech Recent Developments
8.14 Coherus BioSciences
8.14.1 Coherus BioSciences Comapny Information
8.14.2 Coherus BioSciences Business Overview
8.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.14.5 Coherus BioSciences Recent Developments
8.15 Celltrion
8.15.1 Celltrion Comapny Information
8.15.2 Celltrion Business Overview
8.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.15.5 Celltrion Recent Developments
8.16 Boehringer Ingelheim Pharmaceuticals
8.16.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
8.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
8.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
8.17 Biocon Biologics
8.17.1 Biocon Biologics Comapny Information
8.17.2 Biocon Biologics Business Overview
8.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.17.5 Biocon Biologics Recent Developments
8.18 Amgen
8.18.1 Amgen Comapny Information
8.18.2 Amgen Business Overview
8.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.18.5 Amgen Recent Developments
8.19 AbbVie
8.19.1 AbbVie Comapny Information
8.19.2 AbbVie Business Overview
8.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2020-2025)
8.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
8.19.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
9.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Mode & Process
9.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
9.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.